UY26135A1 - Compuestos de benzolactama sustituidos - Google Patents

Compuestos de benzolactama sustituidos

Info

Publication number
UY26135A1
UY26135A1 UY26135A UY26135A UY26135A1 UY 26135 A1 UY26135 A1 UY 26135A1 UY 26135 A UY26135 A UY 26135A UY 26135 A UY26135 A UY 26135A UY 26135 A1 UY26135 A1 UY 26135A1
Authority
UY
Uruguay
Prior art keywords
compounds
alkyl
halo
alkoxy
substituted
Prior art date
Application number
UY26135A
Other languages
English (en)
Inventor
Susan Beth Sobolov-Jaynes
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY26135A1 publication Critical patent/UY26135A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Abstract

Compuestos de benzolactama y tioamida cíclica, sistituidos, incluyendo sus sales farmacéuticamente aceptables, que tienen un valor especial en vista de su capacidad de antagonizar la acción de la sustancia P (neuropéptido farmacéuticamente activo que se sintetiza en mamíferos y que posee una secuencia de aminoácidos característica). Compuestos de la fórmula general (I) o una sal farmacéuticamente aceptable de los mismos, en la que: W es metileno, etileno, propileno, vinileno, CH2-O, O-CH2, CH2-S ó S-CH2; R1, R2 y R3 son independientemente hidrógeno, alquilo, alcoxi-alquilo o halo-alquilo, con la condición de que cuando W es metileno, ni R2 ni R3 sean hidrógeno; o uno de R2 o R3 puede ser hidroxi; X es halo, alcoxi, alquilo, halo-alcoxi o alquenilo; Y es NH u O; Q es oxígeno o azufre y presenta un doble enlace con el carbono al que está unido, o Q es CH3 y presenta un enlace sencillo con el carbono al que está unido; T es (2S,3S)-2-difenilmetilquinuclidin-3-ilo, (2S,3S)-2-difenilmetil-1-azanorbornan-3-ilo; o (2S,3S)-2-fenilpiperidin-3-ilo, estando el grupo fenilo de este último pocionalmente sustituido con uno o más sustituyentes. Por ejemplo: Monomesilato de (2S,3S)-2-difenilmetil-3-(6-metoxi-1,3,3-trimetiloxindol-5-il)-metilamino-1-azabiciclo(2.2.2)octano. Procedimientos de tratamiento de diversos trastornos del SNC y de otros trastornos usando dichos compuestos y composiciones farmaceúticas de los mismos.
UY26135A 1999-05-06 2000-05-03 Compuestos de benzolactama sustituidos UY26135A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13285899P 1999-05-06 1999-05-06

Publications (1)

Publication Number Publication Date
UY26135A1 true UY26135A1 (es) 2000-12-29

Family

ID=22455915

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26135A UY26135A1 (es) 1999-05-06 2000-05-03 Compuestos de benzolactama sustituidos

Country Status (40)

Country Link
EP (1) EP1175417B1 (es)
JP (1) JP2002544128A (es)
KR (1) KR20020015319A (es)
CN (1) CN1349527A (es)
AP (1) AP2001002314A0 (es)
AR (1) AR036320A1 (es)
AT (1) ATE257478T1 (es)
AU (1) AU3572800A (es)
BG (1) BG106141A (es)
BR (1) BR0010673A (es)
CA (1) CA2373079A1 (es)
CR (1) CR6505A (es)
CZ (1) CZ20013977A3 (es)
DE (1) DE60007625T2 (es)
DK (1) DK1175417T3 (es)
DZ (1) DZ3040A1 (es)
EA (1) EA200101050A1 (es)
EE (1) EE200100586A (es)
ES (1) ES2211520T3 (es)
GE (1) GEP20043224B (es)
GT (1) GT200000063A (es)
HK (1) HK1046144A1 (es)
HR (1) HRP20010821A2 (es)
HU (1) HUP0201135A3 (es)
IL (1) IL145945A0 (es)
IS (1) IS6122A (es)
MA (1) MA26731A1 (es)
MY (1) MY133207A (es)
NO (1) NO20015395L (es)
NZ (1) NZ514697A (es)
OA (1) OA11864A (es)
PA (1) PA8494901A1 (es)
PE (1) PE20010119A1 (es)
PL (1) PL351919A1 (es)
PT (1) PT1175417E (es)
TN (1) TNSN00095A1 (es)
TR (1) TR200103222T2 (es)
UY (1) UY26135A1 (es)
WO (1) WO2000068224A1 (es)
ZA (1) ZA200109116B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108982D0 (en) 2001-04-10 2001-05-30 Merck Sharp & Dohme Therapeutic agents
JPWO2003055858A1 (ja) * 2001-12-27 2005-05-12 東レ・ファインケミカル株式会社 １−アルコキシカルボニル含窒素飽和複素環誘導体の製造法
ATE471722T1 (de) 2003-03-12 2010-07-15 Univ Arizona State Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
WO2009109001A1 (en) * 2008-03-04 2009-09-11 Adelaide Research & Innovation Pty Ltd Method for preventing and/or treating a disease, condition or state associated with reduced dopaminergic neuron function
JP6156074B2 (ja) * 2013-11-08 2017-07-05 住友化学株式会社 スクシンイミド化合物及びその用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2150123C (en) * 1992-12-10 2004-12-07 Harry R. Howard Aminomethylene substituted non-aromatic heterocycles
ATE199552T1 (de) * 1995-07-07 2001-03-15 Pfizer Substituierte benzolaktamverbindungen als substanz-p-antagonisten
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
PT780375E (pt) * 1995-12-21 2002-12-31 Pfizer 3-¬(benzilo substituido em 5)amino|-2-phenilpiperidinas como antagonistas da substancia p
TW426667B (en) * 1997-11-19 2001-03-21 Pfizer Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists

Also Published As

Publication number Publication date
HUP0201135A2 (en) 2002-09-28
BG106141A (bg) 2002-07-31
HUP0201135A3 (en) 2003-05-28
WO2000068224A1 (en) 2000-11-16
PL351919A1 (en) 2003-06-30
BR0010673A (pt) 2002-02-19
EE200100586A (et) 2003-02-17
IS6122A (is) 2001-10-23
NZ514697A (en) 2004-04-30
EP1175417B1 (en) 2004-01-07
DE60007625T2 (de) 2004-11-18
JP2002544128A (ja) 2002-12-24
CZ20013977A3 (cs) 2003-10-15
GEP20043224B (en) 2004-04-26
ES2211520T3 (es) 2004-07-16
HRP20010821A2 (en) 2002-12-31
EP1175417A1 (en) 2002-01-30
CA2373079A1 (en) 2000-11-16
PA8494901A1 (es) 2003-12-10
KR20020015319A (ko) 2002-02-27
GT200000063A (es) 2001-10-27
NO20015395L (no) 2001-12-11
PE20010119A1 (es) 2001-02-06
CN1349527A (zh) 2002-05-15
IL145945A0 (en) 2002-07-25
HK1046144A1 (zh) 2002-12-27
TR200103222T2 (tr) 2002-03-21
OA11864A (en) 2006-03-03
MA26731A1 (fr) 2004-12-20
EA200101050A1 (ru) 2002-04-25
NO20015395D0 (no) 2001-11-05
CR6505A (es) 2004-03-24
PT1175417E (pt) 2004-04-30
AP2001002314A0 (en) 2001-12-31
AR036320A1 (es) 2004-09-01
DK1175417T3 (da) 2004-04-05
TNSN00095A1 (fr) 2005-11-10
MY133207A (en) 2007-10-31
ATE257478T1 (de) 2004-01-15
ZA200109116B (en) 2002-11-05
DE60007625D1 (de) 2004-02-12
DZ3040A1 (fr) 2004-03-27
AU3572800A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
AP2001002299A0 (en) Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents.
ATE273305T1 (de) Thrombin-inhibitoren
MA26880A1 (fr) Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation.
ECSP034660A (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
EP1312601A4 (en) CARBOXYLENE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE SUBSTANCE
PT928788E (pt) Compostos farmaceuticamente activos
EA200101077A1 (ru) Композиция для профилактики или лечения слабоумия, включающая производное гидроксикоричной кислоты или экстракт растения рода angelicae, содержащий его
UY26135A1 (es) Compuestos de benzolactama sustituidos
DK1157998T3 (da) Heterocykliske forbindelser, mellemprodukter derfor og elastaseinhibitorer
EA200100916A1 (ru) Лекарственное средство, содержащее производное сульфопиранозилацилглицерина
AR029001A1 (es) Derivados de bencil-3,4-metilendioxicinamico y el uso de los mismos para la manufactura de un medicamento
BG105123A (en) Tetrahydroquinaline derivatives as glycine antagonists
DK1106614T3 (da) 5-leddede, heteroarylsubstituerede 1,4-dihydropyridinforbindelser som bradykininantagonister
AR026936A1 (es) Compuestos heterociclicos y composiciones que los contienen
UY28618A1 (es) Nuevos indoles sustituidos de piperidina o heteroderivados de los mismos
WO2002024711A1 (fr) Nouveaux composes bicycliques thiazole
DK1065206T3 (da) Tetrazolylalkylindol-forbindelser som anti-inflammatoriske og analgetiske midler
ECSP993005A (es) Compuestos de sulfonilbenceno como agentes anti-inflamatorios / analgesicos
RU94039294A (ru) Производные эпоксиянтарной кислоты и фармацевтическая композиция на их основе

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20101022